Breaking News

BeiGene Earns Merck Serono Milestone

May 5, 2014

BGB-283 BRAF inhibitor achieves clinical milestone

BeiGene, Co. has achieved a clinical milestone in its collaboration with Merck Serono for BGB-283, a second-generation BRAF inhibitor candidate in Phase I development, triggering a $5 million payment from Merck.
 
The companies entered the BGB-283, two-asset strategic collaboration in 2013. In December 2013, BeiGene began a Phase I trial of BGB-283 in patients with BRAF or KRAS mutations. The drug offers the potential to treat cancers that harbor BRAF mutations and/or aberrations in the RAS-MAPK (mitogen-activated protein kinase) pathway.
 
“We are very pleased to successfully reach this development milestone for BGB-283, as this exciting oncology candidate demonstrates the potential of BeiGene’s innovative translational research platform to deliver targeted therapeutics that address the unmet need of cancer patients,” said John V. Oyler, chief executive officer of BeiGene. “We look forward to working with Merck Serono as it continues to progress through the clinic.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent